Kenneth LaPensee
Owner and Principal in Hampton, New Jersey
An experienced healthcare and biopharmaceutical administrator, Kenneth LaPensee has completed a range of market access and pharmacoeconomic support projects with an emphasis on medical products that treat infectious disease, psychiatric issues and conditions of the central nervous system. Kenneth LaPensee’s efforts include writing a pharmacoeconomic report for a phase 4 study that employed escitalopram, conducting a survey of American investors for a new memantine indication for the treatment of Alzheimer’s disease, and analyzing pharmacoeconomic data for the manufacturer of an anticonvulsant medication that reduced patient seizures by 25 percent.
After working for prominent pharmaceutical developers such as The Medicines Company and the Forest Research Institute, Kenneth LaPensee went into business for himself in 2014 as the owner and principal of Skylands Healthcare Consulting LLC in Hampton, New Jersey. Functioning as an independent consultant through Skylands, Mr. LaPensee has consulted with organizations such as Da Volterra and the Gerson Lehrman Group. He is currently contracting as an internal health economics and outcomes research professional for Paratek Pharmaceuticals.